Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ROTH Webinar - Enanta Pharmaceuticals (ENTA) - Registration
Topic
ROTH Webinar - Enanta Pharmaceuticals (ENTA) - Oct 1, 2020 – 1:00 PM (ET) / 10:00 AM (PT)
https://roth.zoom.us/webinar/register/WN_9ClZOYqRQtS3r_4Kc7kpag
Revance price target raised to $35 from $32 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance Therapeutics to $35 from $32 and keeps an Overweight rating on the shares after hosting an expert call with a physician treating neuromuscular injuries. If approved, Revance's DaxibotulinumtoxinA would be the only neurotoxin for plantar fasciitis use, Prasad tells investors in a research note.
Read more at:
https://thefly.com/n.php?id=3166413
Revance price target raised to $35 from $32 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance Therapeutics to $35 from $32 and keeps an Overweight rating on the shares after hosting an expert call with a physician treating neuromuscular injuries. If approved, Revance's DaxibotulinumtoxinA would be the only neurotoxin for plantar fasciitis use, Prasad tells investors in a research note.
Read more at:
https://thefly.com/n.php?id=3166413
Enanta management to meet virtually with Roth Capital 12:23 ENTA Webinar with management will be held on October 1 at 1 pm hosted by Roth Capital.
Read more at:
https://thefly.com/n.php?id=3165596
Dew - any info on RVNC - huge volume & UP?
ENANTA PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDY OF EDP-297, ITS HIGHLY POTENT AND TARGETED FOLLOW-ON FARNESOID X RECEPTOR AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
SEPTEMBER 14, 2020
-- Initial clinical data including safety, tolerability and pharmacokineticsexpected in 2Q 2021 –
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subjects in its Phase 1 clinical trial of EDP-297, a highly potent and targeted follow-on farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
“We are excited to advance our efforts in NASH and progress EDP-297, our follow-on FXR agonist, into clinical development,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “In preclinical studies, EDP-297 demonstrated a compelling product profile, with a potency greater than that published on any FXR agonist in clinical development and high target-tissue distribution in the liver and intestine. Based on these data, we believe we may be able to effectively dose EDP-297 at lower doses and with reduced drug levels in non-targeted tissues, potentially improving tolerability by reducing pruritis. We look forward to reporting clinical data in the second quarter of 2021.”
Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Initiates-Phase-1-Clinical-Study-of-EDP-297-its-Highly-Potent-and-Targeted-Follow-On-Farnesoid-X-Receptor-Agonist-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis/default.aspx
ENANTA PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDY OF EDP-297, ITS HIGHLY POTENT AND TARGETED FOLLOW-ON FARNESOID X RECEPTOR AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
SEPTEMBER 14, 2020
-- Initial clinical data including safety, tolerability and pharmacokineticsexpected in 2Q 2021 –
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subjects in its Phase 1 clinical trial of EDP-297, a highly potent and targeted follow-on farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
“We are excited to advance our efforts in NASH and progress EDP-297, our follow-on FXR agonist, into clinical development,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “In preclinical studies, EDP-297 demonstrated a compelling product profile, with a potency greater than that published on any FXR agonist in clinical development and high target-tissue distribution in the liver and intestine. Based on these data, we believe we may be able to effectively dose EDP-297 at lower doses and with reduced drug levels in non-targeted tissues, potentially improving tolerability by reducing pruritis. We look forward to reporting clinical data in the second quarter of 2021.”
Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Initiates-Phase-1-Clinical-Study-of-EDP-297-its-Highly-Potent-and-Targeted-Follow-On-Farnesoid-X-Receptor-Agonist-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis/default.aspx
Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference
September 08 2020 - 04:05PM
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the Morgan Stanley 18th Annual Global Healthcare Conference, a fully virtual management access conference, taking place September 14-18.
President and Chief Executive Officer, Mark Foley, is scheduled to participate in a virtual fireside chat on Monday, September 14, at 2:15 p.m. PT / 5:15 p.m. ET.
https://investors.revance.com/news-releases/news-release-details/revance-participate-morgan-stanley-18th-annual-global-healthcare
5 Questions with Mark Foley, CEO of Revance Therapeutics
Although interview takes place in April, quite relevant today -
Enanta resumed with a Buy at Roth Capital
08/27 ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.
https://thefly.com/n.php?id=3152704
“On September 2, 2020, a purported stockholder of Momenta filed a complaint in the United States District Court for the District of Delaware against Momenta and its directors, captioned Elaine Wang v. Momenta Pharmaceuticals, Inc., et al., Case No. 1:20-cv-01175-UNA. The complaint names as defendants Momenta and each member of the Momenta Board. The complaint alleges that the Schedule 14D-9 omits material information or contains misleading disclosures and that, as a result, (a) all defendants violated Section 14(e) of the Exchange Act, (b) all defendants violated Section 14(d)(4) of the Exchange Act and (c) each member of the Momenta Board violated Section 20(a) of the Exchange Act. The complaint seeks, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement, (ii) rescissory damages or rescission in the event that the transactions contemplated by the Merger Agreement have already been consummated, (iii) damages and (iv) plaintiff’s attorneys’ and experts’ fees and expenses. Momenta believes the claims asserted in the complaint are without merit.
Additional complaints may be filed against Momenta, the Momenta Board, Johnson & Johnson and/or Purchaser in connection with the transactions contemplated by the Merger Agreement, the Schedule TO and the Schedule 14D-9. If such additional complaints are filed, absent new or different allegations that are material, Johnson & Johnson and Purchaser will not necessarily announce such additional complaints.”
https://ih.advfn.com/stock-market/NASDAQ/momenta-pharmaceuticals-MNTA/stock-news/83205233/amended-tender-offer-statement-by-third-party-sc-t
FWIW -
Investor wants to stop the company's $6.5 billion sale to Johnson & Johnson until Momenta supplies shareholders with complete information about the company's financial projections, according to a lawsuit filed Wednesday in Delaware federal court.7 hours ago
(law.com - subscription needed)
ENANTA PHARMACEUTICALS TO PARTICIPATE IN UPCOMING SEPTEMBER CONFERENCES
SEPTEMBER 03, 2020
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual conferences in September:
Baird 2020 Global Healthcare Conference, Fireside Chat at 9:40 a.m. ET on September 10, 2020
H.C. Wainwright 22nd Annual Global Investment Conference, Presentation at 1:00 p.m. ET on September 15, 2020
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Presentation at 3:20 p.m. ET on September 22, 2020
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-to-Participate-in-Upcoming-September-Conferences/default.aspx
ENANTA PHARMACEUTICALS TO PARTICIPATE IN UPCOMING SEPTEMBER CONFERENCES
SEPTEMBER 03, 2020
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual conferences in September:
Baird 2020 Global Healthcare Conference, Fireside Chat at 9:40 a.m. ET on September 10, 2020
H.C. Wainwright 22nd Annual Global Investment Conference, Presentation at 1:00 p.m. ET on September 15, 2020
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Presentation at 3:20 p.m. ET on September 22, 2020
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-to-Participate-in-Upcoming-September-Conferences/default.aspx
Revance to Participate in the Wells Fargo Securities Healthcare Conference....2 September
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the Wells Fargo Securities Healthcare Conference, a fully virtual management access conference, taking place September 9-10.
President and Chief Executive Officer, Mark Foley, is scheduled to present on Wednesday, September 9, at 10:20 a.m. PT / 1:20 p.m. ET
https://finance.yahoo.com/news/revance-participate-wells-fargo-securities-120000389.html
Suggestion - here's another bio I purchased with MNTA funds -
https://www.revance.com/ (check news, etc.)
May I say that Dew recommended such. Noble DEW - muchas gracias.
ENANTA PHARMACEUTICALS PRESENTS NEW DATA FROM ITS HEPATITIS B AND NON-ALCOHOLIC STEATOHEPATITIS PROGRAMS AT THE DIGITAL INTERNATIONAL LIVER CONGRESS™ 2020
AUGUST 28, 2020
New Pharmacokinetic and Safety Results from Phase 1a Study of HBV Core Inhibitor EDP-514, Highlighting Good Safety and Tolerability, and Pharmacokinetics Suitable for Once Daily Dosing
Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transaminase and Liver Fat Content Reduction
Preclinical Findings for Follow-on FXR Agonist EDP-297 Targeting NASH, Demonstrating Potent Anti-Fibrotic, Anti-Inflammatory and Hepatoprotective Effects
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020.
Data presented include results from the Phase 1a clinical trial of EDP-514, Enanta’s core inhibitor for HBV. Additionally, Enanta’s NASH program will be discussed in an oral presentation detailing the Phase 2a ARGON-1 study of EDP-305, Enanta’s lead Farnesoid Xreceptor (FXR) agonist, and two posters highlighting preclinical data on EDP-297, Enanta’s follow-on FXR agonist.
“We are pleased to share scientific data across multiple candidates in our pipeline, supporting our chemistry-driven approach to developing innovative treatments for viral infections and liver diseases,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “The positive results from our first-in-human Phase 1a study of EDP-514, demonstrating a strong safety, tolerability and pharmacokinetic profile, gave us the confidence to advance our HBV program into two ongoing Phase 1b clinical studies in HBV patients. Additionally, the data presented for our NASH candidates further demonstrate the potential of both FXR agonists. EDP-305 shows statistically significant improvements in liver biochemistry and hepatic steatosis, and our follow-on NASH candidate EDP-297 demonstrates a potent anti-fibrotic effect.”
August 28, 2020, 12:15 PM - 12:30 PM CEST
Additional - Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Presents-New-Data-from-its-Hepatitis-B-and-Non-Alcoholic-Steatohepatitis-Programs-at-the-Digital-International-Liver-Congress-2020/default.aspx
ENANTA PHARMACEUTICALS PRESENTS NEW DATA FROM ITS HEPATITIS B AND NON-ALCOHOLIC STEATOHEPATITIS PROGRAMS AT THE DIGITAL INTERNATIONAL LIVER CONGRESS™ 2020
AUGUST 28, 2020
New Pharmacokinetic and Safety Results from Phase 1a Study of HBV Core Inhibitor EDP-514, Highlighting Good Safety and Tolerability, and Pharmacokinetics Suitable for Once Daily Dosing
Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transaminase and Liver Fat Content Reduction
Preclinical Findings for Follow-on FXR Agonist EDP-297 Targeting NASH, Demonstrating Potent Anti-Fibrotic, Anti-Inflammatory and Hepatoprotective Effects
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020.
Data presented include results from the Phase 1a clinical trial of EDP-514, Enanta’s core inhibitor for HBV. Additionally, Enanta’s NASH program will be discussed in an oral presentation detailing the Phase 2a ARGON-1 study of EDP-305, Enanta’s lead Farnesoid Xreceptor (FXR) agonist, and two posters highlighting preclinical data on EDP-297, Enanta’s follow-on FXR agonist.
“We are pleased to share scientific data across multiple candidates in our pipeline, supporting our chemistry-driven approach to developing innovative treatments for viral infections and liver diseases,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “The positive results from our first-in-human Phase 1a study of EDP-514, demonstrating a strong safety, tolerability and pharmacokinetic profile, gave us the confidence to advance our HBV program into two ongoing Phase 1b clinical studies in HBV patients. Additionally, the data presented for our NASH candidates further demonstrate the potential of both FXR agonists. EDP-305 shows statistically significant improvements in liver biochemistry and hepatic steatosis, and our follow-on NASH candidate EDP-297 demonstrates a potent anti-fibrotic effect.”
August 28, 2020, 12:15 PM - 12:30 PM CEST
Additional - Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Presents-New-Data-from-its-Hepatitis-B-and-Non-Alcoholic-Steatohepatitis-Programs-at-the-Digital-International-Liver-Congress-2020/default.aspx
THANK YOU, dear friends for your parting kind words.
Here's one of the bios that I have invested with MNTA funds:
28 August:
Enanta resumed with a Buy at Roth Capital. ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.
Read more at:
https://thefly.com/n.php?id=3152704
THANK YOU, DEW -
28 August:
Enanta resumed with a Buy at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.
Read more at:
https://thefly.com/n.php?id=3152704
Dew - right on!
28 August:
Enanta resumed with a Buy at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.
Read more at:
https://thefly.com/n.php?id=3152704
Initiating coverage - ENTA - With a current rating of Overweight, Piper Sandler initiated coverage on Enanta Pharmaceuticals Inc (NASDAQ: ENTA). The price target seems to have been set at $87.00 for Enanta Pharmaceuticals. Enanta Pharmaceuticals earned $0.71 in the third quarter, compared to $0.33 in the year-ago quarter. The stock has a 52-week-high of $73.39 and a 52-week-low of $38.40. At the end of the last trading period, Enanta Pharmaceuticals closed at $50.64.
https://finance.yahoo.com/news/benzingas-top-upgrades-downgrades-august-134200366.html
Initiating coverage - ENTA - With a current rating of Overweight, Piper Sandler initiated coverage on Enanta Pharmaceuticals Inc (NASDAQ: ENTA). The price target seems to have been set at $87.00 for Enanta Pharmaceuticals. Enanta Pharmaceuticals earned $0.71 in the third quarter, compared to $0.33 in the year-ago quarter. The stock has a 52-week-high of $73.39 and a 52-week-low of $38.40. At the end of the last trading period, Enanta Pharmaceuticals closed at $50.64.
https://finance.yahoo.com/news/benzingas-top-upgrades-downgrades-august-134200366.html
Hello - goodbye
To all my good friends & fellow Momenta Alums. I have taken my MNTA $$Millions & with Elvis - left the building.
This A.M. I switched to 2 promising biotechs that I have been following recently. And, with encouragement from Dew, I have been re-born.
Bittersweet, but life goes on.
Stay well - success & happiness to all.
SIR FLO
Momenta initiated with a Market Perform at Raymond James 17:09 MNTA, JNJ Raymond James analyst Danielle Brill initiated coverage of Momenta (MNTA) with a Market Perform rating. The analyst notes that she had considered the company to be an "attractive" takeout candidate, but was surprised that Johnson & Johnson (JNJ) was the bidder. Brill adds that the deal will draw the attention of other Big Pharma companies to the FcRn class, though she expects no closing issues in the acquisition.
Read more at:
https://thefly.com/n.php?id=3150700
Here's another patent gift for J&J. Total is now 532 patents.
METHODS FOR PREDICTING RESPONSE TO TREATMENT..13 August
Abstract:
Described herein are methods for treating rheumatoid arthritis by determining whether a subject having rheumatoid arthritis will respond to an anti-TNF-alpha therapy based on the number of innate and adaptive immune cells in a sample from the subject prior to treatment.
BACKGROUND
[0002] Most patients initiating biologic therapy for rheumatoid arthritis are put on anti-TNF-alpha treatment as the first line treatment. However, approximately 30% of patients do not respond to anti-TNF-alpha treatment, and their disease often progresses before their non-response can be clinically determined. Although studies have been focused on understanding the biology underlying non-response in these patients, this remains an area of active investigation. As a result, new methods are needed for determining ahead of time whether a particular rheumatoid arthritis patient will respond to anti-TNF-alpha therapy, so that an effective drug that the patient is likely to respond to can be administered. This will help drive better treatment outcomes and reduce the burden on the healthcare system.
Read more:
https://worldwide.espacenet.com/publicationDetails/description?CC=US&NR=2020256851A1&KC=A1&FT=D&ND=3&date=20200813&DB=EPODOC&locale=en_EP
A white knight or a higher offer from J&J??
Published Friday, the 21st
Momenta call volume above normal and directionally bullish
12:45 MNTA Bullish option flow detected in Momenta with 3,745 calls trading, 1.9x expected, and implied vol increasing over 1 point to 8.06%. Dec-20 52.5 calls and Oct-20 52.5 calls are the most active options, with total volume in those strikes near 2,400 contracts. The Put/Call Ratio is 0.17. Earnings are expected on October 29th.
Read more at:
https://thefly.com/n.php?id=3150015
Gentlemen of the (open) BAR - FUN & BOING et al -
I, too, feel badly for Tony. If he had only announced his intentions prior, it would have been quite easy for us to dissuade him.
My financial management team's opinion is that Goldman Sachs main focus was on getting a fair price for all shareholders. (Personally, I tend to disagree in terms we've already stated.) Furthermore, they advised me to see how the dice falls in the next several weeks & not contact any of the ambulance chasers. You can be sure that they (class action suit attorneys) will contact us if the chips fall negatively or they ass u me they can "extort" multi-millions.
___________________________________________
Here's something quite interesting that was actually posted on the MNTA's IH page -
On August 19, 2020, Mr. Craig Wheeler, the Company’s Chief Executive Officer, provided the following electronic communication to its employees:
All,
Today we announced that Momenta has agreed to be acquired by Johnson & Johnson. I know this comes as a surprise to many of you. News like this brings with it many emotions. It will take some time for each of us to process. In this note I want to provide you with an overview of the facts to help you better understand what is ahead, as well as share some of my perspectives on the acquisition. We will also hold an employee all hands meeting this morning at 10:00 a.m. to provide more detailed information. Please bring your questions and we will explore them together. For contractors and co-ops, your manager will be reaching out to you soon with more information.
Acquisitions are a part of public company life and we often cannot control when or how they happen. J&J is a first-class company which shares our mission and key elements of our culture. Their offer recognizes the value we have created for patients and shareholders with the strong portfolio we have built and shepherded into development. J&J also recognizes the value of our team. They plan to keep Momenta’s presence in Cambridge and use it to build a greater J&J footprint in the Boston area. This is an important recognition of the value we have created for patients and the contributions our culture and team can bring to J&J.
J&J has been very thoughtful in how they are approaching Momenta’s integration into the J&J family of companies. At close, the company will remain intact, with all employees, including executive team members, asked to stay on to work with the J&J team. Together we will define how Momenta integrates into the J&J organization. They have also agreed to accelerate all outstanding stock and option grants for employees. This means that any annual grants you have outstanding, as well as the second tranche of performance shares you were expecting next year, will all be paid out to you when the deal closes. Ultimately, there will be some changes as the direction gets re-defined. The agreement also assures that if some ultimately do leave us, Momenta’s severance practice will be honored, and employee support services will be strong. J&J is clearly a people focused company, which is important as it has always been one of our key values.
In the coming weeks we will move from signing the deal to a final close. We expect this to take between one and four months, with closing expected before the end of the year. During this period between sign and close, Johnson & Johnson will commence a tender offer for all outstanding shares of Momenta stock, and we will jointly complete the filings necessary for regulatory approval. While that is all going on, we will continue to operate as an independent company.
This period between signing and closing of the deal will allow some time for J&J management to introduce themselves to Momenta. During these few weeks we will also work together to finalize plans for operations of Momenta immediately after the deal is closed. As per our agreement, we will seek input from J&J on certain decisions before the deal closes but will continue to run our business until the transaction is finalized. At closing we will formally become part of the J&J family. This process will start on Thursday, with a town hall style All Hands meeting where J&J leadership will introduce themselves to everyone, including a Q&A session to answer your questions.
I want to give you some perspectives on how to think about this acquisition. For a transition like this one, we will all need to process it in our own way. There is always a sense of loss and grieving that we must contend with. But it is also an opportune moment for rebirth as we work to shape the new destiny of our organization and ourselves. If we take advantage of this inflection point, each of us will grow in our own way and we may find opportunities we never knew existed.
As a part of J&J, our portfolio will be funded with resources far greater than we could muster on our own. I have gotten to know several of their executives. They are warm and compassionate people who truly have an interest in maintaining the spirit of Momenta as they work to integrate the company and take our programs forward. I am also convinced of the commitment their executives have to our vision for the company. They are fully committed to advancing nipocalimab in fetal maternal medicine: they are after all “the baby company”! Their global commercial reach and their mission to invest in rare disease medicine are a fantastic match for the broad portfolio we have begun to assemble. I believe that we can be much more together than we could achieve our own. As a part of J&J, our drug candidates will reach even more of the patients who desperately need them.
Approach this acquisition with a lens to all the opportunity this can create for Momenta and you, as we become a part of a great organization which also happens to be the largest and most successful health care company in the world.
Thank you all,
Craig
More important Q & A continues:
https://ih.advfn.com/stock-market/NASDAQ/momenta-pharmaceuticals-MNTA/stock-news/83104052/written-communication-by-the-subject-company-relat
How much is each patent worth?
INESTIMABLE value
This is the crux, the essence of any company's total worth.
Lest we forget -
I'm madder than the mad hatter!
CW - take it all - including the intellectual property - PATENT ESTATE.
Approximately 530 results found in the Worldwide database for:
Momenta Pharmaceuticals as the applicant.
https://worldwide.espacenet.com/searchResults?submitted=true&locale=en_EP&DB=EPODOC&ST=advanced&TI=&AB=&PN=&AP=&PR=&PD=&PA=momenta%20pharmaceuticals&IN=&CPC=&IC=
WTF - Is this worth ZERO?
Momenta downgraded to Hold from Buy at Truist 07:11 MNTA, JNJ Truist analyst Robyn Karnauskas downgraded Momenta (MNTA) to Hold from Buy with an unchanged $53 price target after its announcement of an acquisition by Johnson & Johnson (JNJ). The analyst also sees some "potential upside risk" to her price target and rating in the event of an increase in acquisition price due to interlopers or bidding in the ongoing acquisition process.
Read more at:
https://thefly.com/n.php?id=3149117
Furthermore -
JNJ noted that the acquisition is driven by the opportunity for nipocalimab and MNTA’s scientific capability in autoantibody driven disease, with additional assets in MNTA’s pipeline to be further evaluated as more data become available. JNJ is also to retain MNTA’s presence in Cambridge, MA to increase JNJ’s existing innovation footprint and capabilities in the greater Boston area.
FWIW - Have we been screwed??
Momenta downgraded to Equal Weight from Overweight at Wells Fargo 09:39 MNTA Wells Fargo analyst Yanan Zhu downgraded Momenta (MNTA) to Equal Weight from Overweight with a price target of $52.50, up from $48, after the company announced plans to be acquired by Johnson & Johnson (JNJ) for $52.50 per share. Zhu believes the $6.5B acquisition value is consistent with the broad opportunity represented by Momenta's lead FcRn asset nipocalimab across various autoantibody-driven diseases given its best-in-class potency in antibody reduction.
Read more at:
https://thefly.com/n.php?id=3148645
Thank you, Vinnie, & all my biotech friends on Biotech Values.
Again, DEW, you are the ONE - not, KEANU.
Remember this - why not a Chinese company now?
The job losses began almost immediately. All of them involve China. Momenta Pharmaceuticals, a Boston-area biotech, experienced the collapse of a proposed spinout of part of its business to a syndicate of China-based investors over concerns about CFIUS, said CEO Craig Wheeler, leading to the company’s September, 2018, partial shutdown. The impact: 110 lost jobs.
Read more:
https://www.forbes.com/sites/stevedickman/2019/05/24/us-crackdown-on-foreign-biotech-investment-makes-us-poorer-not-safer/#5c0571a55819
I have a gut feeling that either MYLAN - @ $16.41 or CSL - @ $211 might be considering a higher bid for MNTA. I prefer a merger where we would receive shares in the new company & not straight- out cash. Time will tell.